Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 1.00 |
| ▸ | GLB1 | P16278 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 5/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GANAB | Q14697 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.46 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyfuconojirimycin SCHEMBL15686574 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL12581516 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL2436650 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL9999893 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL15691930 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13328524 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876087 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL1867289 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876082 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL2435560 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2196758-A | — | — | None | — | — | JP | disclosed |
| US-8242136-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-08-14 | — | — | US | disclosed |
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | UNIVERSITE DE POITIERS (FR) | 2011-11-03 | — | — | US | disclosed |
| US-7973054-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-07-05 | — | — | US | disclosed |
| EP-1411952-B1 | USE OF AT LEAST ONE GLYCOINHIBITOR SUBSTANCE AGAINST INFECTIOUS DISEASES | GLYKOS FINLAND OY (FI) | 2009-04-22 | — | — | EP | disclosed |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-09-13 | — | — | US | disclosed |
| US-20040176320-A1 | Use of at least one glycoinhibitor substance | BIOTIE THERAPIES COPR. (FI) | 2004-09-09 | — | — | US | disclosed |
| EP-1411952-A1 | USE OF AT LEAST ONE GLYCOINHIBITOR SUBSTANCE | Carbion OY (FI) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002127-A1 | USE OF AT LEAST ONE GLYCOINHIBITOR SUBSTANCE | GLYKOS FINLAND OY (FI) | 2003-01-09 | — | — | WO | disclosed |
| EP-0406211-B1 | Fucosidase inhibitors | MONSANTO CO (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0409812-A2 | Fucosidase inhibitor | MONSANTO COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0406211-A2 | Fucosidase inhibitors | MONSANTO COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| JP-H02196758-A | SYNTHESIS OF N-SUBSTITUTED 1,5-DIDEOXY-1,5-IMONO-L-FUCITOL DERIVATIVE | G D SEARLE & CO | 1990-08-03 | — | — | JP | disclosed |
| EP-0363344-A1 | Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives | G.D. SEARLE & COMPANY (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0363344-A1 | Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives | G.D. SEARLE & COMPANY (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0363344-A1 | Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives | G.D. SEARLE & COMPANY (US) | 1990-04-11 | — | — | EP | disclosed |
| US-4910310-A | Esterification of 2,3-O-isopropylidene-D-lyxono-1,4-lactone | G. D. SEARLE & CO. (US) | 1990-03-20 | — | — | US | disclosed |
| US-4910310-A | Esterification of 2,3-O-isopropylidene-D-lyxono-1,4-lactone | G. D. SEARLE & CO. (US) | 1990-03-20 | — | — | US | disclosed |
| US-4910310-A | Esterification of 2,3-O-isopropylidene-D-lyxono-1,4-lactone | G. D. SEARLE & CO. (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0322395-A1 | Heterocyclic compounds for inhibiting virus | Monsanto Company (US) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | MAN2B1, GAA, MAN2A1 | FUCA1 13/4885FUCA2 32/4885GLB1 61/4885 |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | MAN2B1, GAA, MAN2A1 | FUCA1 12/4885FUCA2 35/4885GLB1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.